MOLN News and Press, Molecular Partners AG From 08/24/25

2025-08-24 18:44:46 ET Molecular Partners AG (MOLN) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.13%. The average open to low on the day of earnings was -1.78%. The average open to ...

MP0726, a Radio-DARPin candidate targeting mesothelin (MSLN) and intended for the treatment of ovarian cancer, is nominated for development under strategic partnership with Orano Med Promising tumor accumulation and attractive biodistribution shown in vivo, selective binding to membrane-b...

Three of eight evaluable patients with R/R AML responded after cycle 1 in ongoing cohort 8, including 1 patient with ongoing response beyond 6 months Acceptable safety profile across all cohorts, including in cohort 8 with steeper step-up dosing Data support further dose optimiz...

2025-06-10 04:03:03 ET More on Molecular Partners Molecular Partners: Sluggish Progress But Worth Monitoring (Rating Downgrade) Molecular Partners reports Q1 results Seeking Alpha’s Quant Rating on Molecular Partners Historical earnings data for Molecu...

Guidance confirmed for clinical milestones for MP0533 and MP0712 in H2 2025 Cash reach now anticipated to extend into 2028 ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., June 10, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics (“Molecular Partners” or the &#x...

2025-05-16 05:43:10 ET More on Molecular Partners Molecular Partners: Sluggish Progress But Worth Monitoring (Rating Downgrade) Molecular Partners AG (MOLN) Q4 2024 Earnings Call Transcript Seeking Alpha’s Quant Rating on Molecular Partners Historical ...

Clinical programs on track, with two major milestones later this year, and cash position, CHF 131 million as of March 31, 2025, expected to provide funding well into 2027 IND filing and initial clinical data on first targeted Radio-DARPin therapy program, MP0712, expected in 2025; strateg...

Replimune Group Inc. (REPL) is expected to report $-0.75 for Q4 2025 Adcore (ADCOF) is expected to report for Q1 2025 Equillium Inc. (EQ) is expected to report $-0.22 for Q1 2025 Credicorp Ltd. (BAP) is expected to report $5.31 for Q1 2025 Pelangio Exploration Inc (PGXPF) is expec...

2025-05-13 01:18:58 ET Summary Molecular Partners basically uses DARPins as a modular alternative to monoclonal antibodies in oncology. Their Radio-DARPin collaboration with Orano Med will now use lead-212 for highly localized alpha therapy candidates. However, Novartis droppe...